Sanofi Files Suit in The U.S. To Defend Its Patent Rights on Lantus(R) and Lantus(R) SoloStar(R)

Sanofi Files Suit in The U.S. To Defend Its Patent Rights on Lantus(R) and
Lantus(R) SoloStar(R)

announced today that it filed a patent infringement suit against Eli Lilly and
Company ( "Lilly") on January 30, 2014 in the United States District Court for
the District of Delaware. In its suit Sanofi alleges infringement of four

The suit was triggered by notifications received from Lilly beginning in
mid-December, in which Lilly stated that it had filed a NDA (505(b)(2) New
Drug Application) with FDA for an insulin glargine drug product. Lilly also
stated that its NDA included a paragraph IV certification challenging six of
the seven Sanofi patents listed in the FDA Orange Book for Sanofi's Lantus®
and Lantus® SoloStar® products.

Lilly has also stated that it will not launch its product before the expiry of
Sanofi's patent on the active ingredient in Lantus®, which is in force through
February 12, 2015.

About Sanofi

Sanofi, an integrated global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT:SAN) and in New York (NYSE:SNY).

Forward-Looking Statements

This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product development
and potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans" and similar expressions. Although
Sanofi's management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally beyond the
control of Sanofi, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA, regarding
whether and when to approve any drug, device or biological application that
may be filed for any such product candidates as well as their decisions
regarding labelling and other matters that could affect the availability or
commercial potential of such product candidates, the absence of guarantee that
the product candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group's
ability to benefit from external growth opportunities, trends in exchange
rates and prevailing interest rates, the impact of cost containment policies
and subsequent changes thereto, the average number of shares outstanding as
well as those discussed or identified in the public filings with the SEC and
the AMF made by Sanofi, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual
report on Form 20-F for the year ended December 31, 2012. Other than as
required by applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.


Media Relations             Investor Relations

Jack Cox                    Sébastien Martel

Tel.: +33 (0)1 53 77 46 46 Tel.: +33 (0)1 53 77 45 45     

PDF Version of Press Release

Press spacebar to pause and continue. Press esc to stop.